PromarkerD diabetic kidney disease patent granted in Japan
Filed with ASX · · 2 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Appendix 4C - December 2017 Quarterly Report
- Proteomics joins major health study to target lung disease
- PromarkerD predictive diagnostic test to launch in Q1 2018
- Proteomics partnered consortium to receive $2 million
- Appendix 4C - September 2017 Quarterly Report
Later from Proteomics International Laboratories
- Strategic alliance and investment in CPR Pharma Services
- Proteomics launches PromarkerD
- Proteomics secures underwriting - PIQ Options to raise $3.4m
- Directors Exercise PIQ Options
- Conversion of 90% of Proteomics Options raises of $3m
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories